

## Q: Is there a relationship between hypertension and cognitive function in older adults?

**RONY ABOU JAWDE, MD**

Department of Internal Medicine, The Cleveland Clinic

**BARBARA J. MESSINGER-RAPPORT, MD, PhD**

Section of Geriatric Medicine, Department of Internal Medicine, The Cleveland Clinic

**A:** Yes. There is also evidence suggesting that treatment of chronic hypertension can reduce cognitive decline later in life and even decrease the incidence of dementia due to Alzheimer disease.

### ■ EPIDEMIOLOGY

The incidence of both hypertension and Alzheimer disease increases with age.

The rise of hypertension in the population precedes that of dementia by about 30 years. The prevalence of hypertension increases rapidly between the ages of 30 and 50, then slowly after age 60.<sup>1</sup>

The prevalence of Alzheimer disease is very low before age 60, but increases rapidly after age 75.<sup>2</sup>

However, the relationship between blood pressure and dementia is not linear. Blood pressure may become lower and more variable at the time of clinical manifestation of dementia. This finding has been described in persons with established Alzheimer disease and other types of dementia, such as vascular dementia.<sup>3,4</sup>

### ■ PROPOSED PATHOPHYSIOLOGY

The influence of long-standing hypertension in middle age on cognition late in life may be multifactorial.

**Hypertension is associated with cerebrovascular disease**, which is in turn associated with dementia. For example, multiple small strokes or one unfortunately situated stroke can result in vascular dementia.

Stroke may also affect the course of

Alzheimer disease, which is more common in the United States than vascular dementia. Clinical manifestations of Alzheimer disease may be accelerated by cerebral infarcts. For instance, subjects in the Nun Study<sup>5</sup> who met the neuropathologic criteria for Alzheimer disease and had brain infarcts had poorer cognitive function and a higher prevalence of dementia than those without infarcts. Subjects with lacunar infarcts in the basal ganglia, thalamus, or deep white matter had an especially high prevalence of dementia.

**Abnormalities in cerebral autoregulation seen in chronic hypertension may impair perfusion**, causing impairments in psychomotor function, attention, short-term and long-term memory, and speed of responses.

**There may be one or more genetic links**, such as the gene for apolipoprotein E4, associated with both cardiovascular disease and Alzheimer disease.

### ■ OBSERVATIONAL STUDIES AND COGNITION

Several large observational studies demonstrated a strong relationship between long-standing hypertension and cognitive impairment, especially with untreated hypertension (**TABLE 1**).<sup>6-13</sup> In the Framingham cohort, the relationship was even stronger in diabetic persons with hypertension.<sup>7</sup>

However, the relationship between blood pressure and cognition is complex.<sup>8,9</sup> Blood pressure may decrease to low or normal levels before Alzheimer disease becomes clinically manifest.<sup>14</sup> Studies suggest that this decrease may be a dysregulation resulting from dementia, although a causal relationship cannot be excluded.

There may also be an association between blood pressure variability in hypertensive

Midlife  
hypertension is  
associated with  
impaired  
cognition and  
dementia later

**TABLE 1****Hypertension and risk of cognitive impairment or dementia:  
Large prospective cohort studies**

| STUDY*   | NO.   | AVERAGE AGE AT STUDY ONSET (YEARS) | DURATION (YEARS) | FINDINGS   |
|--|-------|------------------------------------|------------------|--|
| LPS <sup>6</sup>                                 | 382   | 70                                 | 15               | Increased risk of dementia at age 79–85 with high SBP at age 70 or high DBP at age 70 or 75  |
| FHS <sup>7</sup>                                 | 1,811 | 67                                 | 28–30            | Increased risk for falling below 25th percentile on immediate and delayed memory and word fluency with DBP > 90 mm Hg<br>Subgroup with diabetes had even higher risk   |
| EPESE <sup>8</sup>                               | 3,657 | 74                                 | 6–15             | 15% more errors in the SPMSQ if SBP > 160 mm Hg compared with SBP 130–139 mm Hg<br>Suggestion of U-shaped association of errors with lowest blood pressure   |
| EPESE subset with Alzheimer disease <sup>9</sup> | 634   | 72                                 | 6–15             | No association of Alzheimer disease with hypertension 13 years before diagnosis<br>Inverse association of Alzheimer disease with SBP 4 years before diagnosis<br>Inverse association of Alzheimer disease with pulse pressure 4 years before diagnosis |
| Hisayama <sup>10</sup>                           | 828   | 74                                 | 7                | Elevated SBP was an independent predictor of vascular dementia but not Alzheimer disease   |
| Honolulu-Asian <sup>11</sup>                     | 3,735 | 53                                 | 23–28            | 5% increased risk of cognitive impairment for every 10 mm Hg increase in SBP   |
| Western Collaborative <sup>12</sup>              | 717   | 45                                 | 38               | Decreased verbal memory in those with persistent hypertension throughout the study   |
| Twin Study <sup>13</sup>                         | 392   | 47                                 | 25               | Subgroup with highest midlife SBP had largest decline in psychomotor speed and smallest increase in verbal fluency over 10 years<br>This group also had decreased brain volume and increased white matter hyperintensities on MRI                      |

\*LPS = Longitudinal Population Study in Göteborg, FHS = Framingham Heart Study, EPESE = Established Populations for the Epidemiologic Study of the Elderly, SPMSQ = Short Portable Mental State Questionnaire, SBP = systolic blood pressure, DBP = diastolic blood pressure, MRI = magnetic resonance imaging

patients and impaired cognition. In an extension of the Systolic Hypertension in Europe (Syst-Eur) study in older people,<sup>15</sup> blood pressure variability at baseline was positively correlated with the incidence of dementia during the study. This variability may reflect central nervous system dysregulation or occult injury to the prefrontal autonomic centers, occurring just before the clinical manifestation of dementia.

### ■ DOES TREATING HYPERTENSION PREVENT DEMENTIA?

Secondary analyses of two major studies of hypertension in older adults evaluated the risk of dementia in the groups receiving active treatment and placebo.

In the Syst-Eur study,<sup>16</sup> 21 new cases of dementia were found in the 1,180 patients in the placebo group, vs 11 cases in the 1,238



patients receiving the calcium channel blocker nitrendipine, a statistically significant 50% difference. The investigators calculated that treating 53 people for 5 years would prevent 1 case of dementia. Of the incident cases of dementia, 23 were Alzheimer disease, 2 were vascular dementia, and the other 7 were felt to be a mixed dementia.

On the other hand, in the Systolic Hypertension in the Elderly (SHEP) study,<sup>17</sup> no difference in the incidence of dementia was found between the groups receiving the diuretic chlorthalidone (1.6%) and placebo (1.9%).

The difference in findings between these two major studies raises the question of whether the effect on cognitive outcome depends on the drug, or perhaps on the differences in the risk factors between subject populations in the two studies. Interestingly, in a prospective but non-randomized study of 1,301 hypertensive adults older than 75 years,<sup>18</sup> those receiving diuretic monotherapy had a 40% lower incidence of dementia over 3 to 5 years compared with those receiving no treatment.

The relationship between hypertension treatment and incidence of dementia may be clarified further when the results of the SCOPE trial (Study on Cognition and Prognosis in the Elderly) become available. The study is comparing an angiotensin-receptor blocker with placebo.<sup>19</sup>

## RECOMMENDATIONS

- Consider treating chronic hypertension in older adults, not only to prevent cardiovascular and cerebrovascular disease, but also for the possible cognitive benefits.
- The goal for treatment of chronic hypertension in a person without diabetes is 140/90 mm Hg, according to guidelines from the sixth Joint National Committee (JNC VI).<sup>20</sup> For people with diabetes, the goal is 130/85 mm Hg.
- Neither the optimum target blood pressure nor the drug of choice once dementia is diagnosed is known. The JNC VI criteria remain appropriate guidelines for elderly as well as middle-aged adults.

## REFERENCES

1. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. *Hypertension* 1995; 25:305–313.
2. Evans D, Funkenstein H, Albert M, et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. *JAMA* 1989; 262:2551–2556.
3. Skoog I, Andreasson LA, Landahl S, Lernfelt B. A population-based study on blood pressure and brain atrophy in 85-year-olds. *Hypertension* 1998; 32:404–409.
4. Ruitenberg A, Skoog I, Ott A, et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. *Dement Geriatr Cogn Disord* 2001; 12:33–39.
5. Snowdon D, Greiner L, Mortimer J, Riley K, Greiner P, Markesbery W. Brain infarction and the clinical expression of Alzheimer's disease: the Nun Study. *JAMA* 1997; 277:813–817.
6. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. *Lancet* 1996; 347:1141–1145.
7. Elias PK, Elias MF, D'Agostino RB, et al. NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study. *Diabetes Care* 1997; 20:1388–1395.
8. Glynn RJ, Beckett LA, Hebert LE, Morris MC, Scherr PA, Evans DA. Current and remote blood pressure and cognitive decline. *JAMA* 1999; 281:438–445.
9. Morris MC, Scherr PA, Hebert LE, Glynn RJ, Bennett DA, Evans DA. Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. *Arch Neurol* 2001; 58:1640–1646.
10. Yoshitake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. *Neurology* 1995; 45:1161–1168.
11. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. *JAMA* 1995; 274:1846–1851.
12. Swan GE, Carmelli D, Larue A. Systolic blood pressure tracking over 25 to 30 years and cognitive performance in older adults. *Stroke* 1998; 29:2334–2340.
13. Swan GE, DeCarli C, Miller BL, et al. Association of midlife blood pressure to late-life cognitive decline and brain morphology. *Neurology* 1998; 51:986–993.
14. Guo Z, Viitanen M, Winblad B, Fratiglioni L. Low blood pressure and incidence of dementia in a very old sample: dependent on initial cognition. *J Am Geriatr Soc* 1999; 47:723–726.
15. Birkenhäger W, Forette F, Thijs L. Increased blood pressure variability may be associated with cognitive decline in hypertensive elderly subjects with no dementia [letter]. *Arch Intern Med* 2002; 162:484.
16. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. *Lancet* 1998; 352:1347–1351.
17. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA* 1991; 265:3255–3264.
18. Guo Z, Fratiglioni L, Zhu L, Fastbom J, Winblad B, Viitanen M. Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication. *Arch Neurol* 1999; 56:991–996.
19. Hansson L, Lithell H, Skoog I, et al. Study on Cognition and Prognosis in the Elderly (SCOPE): baseline characteristics. *Blood Pressure* 2000; 9:146–151.
20. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Arch Intern Med* 1997; 157:2413–2446.

ADDRESS: Barbara J. Messinger-Rapport, MD, PhD, Section of Geriatric Medicine, A91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [rapporb@ccf.org](mailto:rapporb@ccf.org)